{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:54:14Z","timestamp":1790463254766,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.canlet.2020.12.015","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T01:47:47Z","timestamp":1607996867000},"page":"182-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma"],"prefix":"10.1016","volume":"500","author":[{"given":"Naike","family":"Casagrande","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Borghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6053-8182","authenticated-orcid":false,"given":"Andrea","family":"Favero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2548-4596","authenticated-orcid":false,"given":"Cristina","family":"Vicenzetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4548-3566","authenticated-orcid":false,"given":"Donatella","family":"Aldinucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2020.12.015_bib1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fonc.2017.00292","article-title":"Systemic therapy in metastatic or unresectable well-differentiated\/dedifferentiated liposarcoma","volume":"7","author":"McGovern","year":"2017","journal-title":"Front Oncol"},{"issue":"24","key":"10.1016\/j.canlet.2020.12.015_bib2","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-17-0898","article-title":"FDA approval summary: trabectedin for unresectable or metastatic liposarcoma or leiomyosarcoma following an anthracycline-containing regimen","volume":"23","author":"Barone","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2020.12.015_bib3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14656566.2017.1285282","article-title":"The efficacy of trabectedin in treating ovarian cancer","volume":"18","author":"Teplinsky","year":"2017","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.canlet.2020.12.015_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.14876","article-title":"Enriching cancer pharmacology with drugs of marine origin","volume":"177","author":"Jimenez","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.canlet.2020.12.015_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/bjc.2016.424","article-title":"Antitumour activity of trabectedin in myelodysplastic\/myeloproliferative neoplasms","volume":"116","author":"Romano","year":"2017","journal-title":"Br. J. Cancer."},{"key":"10.1016\/j.canlet.2020.12.015_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/tpj.2016.76","article-title":"A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia","volume":"18","author":"Mannarino","year":"2016","journal-title":"Pharmacogenomics J."},{"issue":"1","key":"10.1016\/j.canlet.2020.12.015_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-019-0714-9","article-title":"Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma","volume":"12","author":"Cuce","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2020.12.015_bib8","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/bjh.15212","article-title":"Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma","volume":"184","author":"Spriano","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2020.12.015_bib9","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1158\/2326-6066.CIR-19-0152","article-title":"Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia","volume":"7","author":"Banerjee","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.canlet.2020.12.015_bib10","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/leu.2016.294","article-title":"Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia","volume":"31","author":"Lohmann","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.canlet.2020.12.015_bib11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-015-2918-1","article-title":"Unique features of trabectedin mechanism of action","volume":"77","author":"Larsen","year":"2016","journal-title":"Canc. Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.canlet.2020.12.015_bib12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/bjc.2014.149","article-title":"Trabectedin, a drug acting on both cancer cells and the tumour microenvironment","volume":"111","author":"D'Incalci","year":"2014","journal-title":"Br. J. Cancer."},{"issue":"7","key":"10.1016\/j.canlet.2020.12.015_bib13","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1158\/0008-5472.CAN-04-4037","article-title":"Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production","volume":"65","author":"Allavena","year":"2005","journal-title":"Canc. Res."},{"issue":"2","key":"10.1016\/j.canlet.2020.12.015_bib14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","article-title":"Role of macrophage targeting in the antitumor activity of trabectedin","volume":"23","author":"Germano","year":"2013","journal-title":"Canc. Cell"},{"issue":"3","key":"10.1016\/j.canlet.2020.12.015_bib15","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ijc.29023","article-title":"Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1","volume":"136","author":"Dossi","year":"2015","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.canlet.2020.12.015_bib16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.canlet.2015.10.007","article-title":"Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance","volume":"380","author":"Aldinucci","year":"2016","journal-title":"Canc. Lett."},{"issue":"10","key":"10.1016\/j.canlet.2020.12.015_bib17","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.3390\/ijms20102416","article-title":"Formation of the immunosuppressive microenvironment of classic Hodgkin lymphoma and therapeutic approaches to counter it","volume":"20","author":"Aldinucci","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2020.12.015_bib18","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3324\/haematol.2018.196725","article-title":"CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth","volume":"104","author":"Casagrande","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2020.12.015_bib19","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/2159-8290.CD-16-0850","article-title":"Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells","volume":"7","author":"Ruella","year":"2017","journal-title":"Canc. Discov."},{"issue":"12","key":"10.1016\/j.canlet.2020.12.015_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114345","article-title":"Macrophages and dendritic cells as actors in the immune reaction of classical Hodgkin lymphoma","volume":"9","author":"Tudor","year":"2014","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.canlet.2020.12.015_bib21","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1158\/2326-6066.CIR-17-0325","article-title":"Complex immune evasion strategies in classical Hodgkin lymphoma","volume":"5","author":"Wein","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2020.12.015_bib22","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3389\/fimmu.2018.01358","article-title":"Hodgkin lymphoma-derived extracellular vesicles change the secretome of fibroblasts toward a CAF phenotype","volume":"9","author":"Dorsam","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.canlet.2020.12.015_bib23","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.mayocp.2015.03.025","article-title":"Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: evaluation based on data from 1450 patients","volume":"90","author":"Tadmor","year":"2015","journal-title":"Mayo Clin. Proc."},{"issue":"10","key":"10.1016\/j.canlet.2020.12.015_bib24","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.canlet.2020.12.015_bib25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2295","article-title":"Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma","volume":"35","author":"Gotti","year":"2017","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.canlet.2020.12.015_bib26","first-page":"e573","article-title":"The lymphoma-associated macrophage to hodgkin-reed-sternberg cell ratio is a poor prognostic factor in classic Hodgkin lymphoma patients. Clin. Lymphoma myeloma","volume":"19","author":"Prochazka","year":"2019","journal-title":"Leuk"},{"key":"10.1016\/j.canlet.2020.12.015_bib27","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/1078-0432.CCR-18-1133","article-title":"Targeting cancer cells and tumor microenvironment in preclinical and clinical models of Hodgkin lymphoma using the dual PI3Kdelta\/gamma inhibitor RP6530","volume":"25","author":"Locatelli","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2020.12.015_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.canlet.2020.12.015_bib29","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ajh.25071","article-title":"Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management","volume":"93","author":"Ansell","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"15","key":"10.1016\/j.canlet.2020.12.015_bib30","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1182\/blood-2017-09-772681","article-title":"Management of relapsed\/refractory classical Hodgkin lymphoma in transplant-ineligible patients","volume":"131","author":"Mehta-Shah","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canlet.2020.12.015_bib31","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1186\/s12885-018-4703-0","article-title":"Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model","volume":"18","author":"Kiyuna","year":"2018","journal-title":"BMC Canc."},{"issue":"3","key":"10.1016\/j.canlet.2020.12.015_bib32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood-2009-12-257345","article-title":"Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome","volume":"116","author":"Steidl","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2020.12.015_bib33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-5-47","article-title":"Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols","volume":"5","author":"Greaves","year":"2012","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2020.12.015_bib34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/carcin\/bgy177","article-title":"Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma","volume":"40","author":"Carminati","year":"2019","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.canlet.2020.12.015_bib35","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12943-019-1029-8","article-title":"The role of necroptosis in cancer biology and therapy","volume":"18","author":"Gong","year":"2019","journal-title":"Mol. Cancer."},{"issue":"2","key":"10.1016\/j.canlet.2020.12.015_bib36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.immuni.2013.02.003","article-title":"Necroptosis: the release of damage-associated molecular patterns and its physiological relevance","volume":"38","author":"Kaczmarek","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2020.12.015_bib37","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3390\/cancers11111687","article-title":"Fibroblasts in nodular sclerosing classical Hodgkin lymphoma are defined by a specific phenotype and protect tumor cells from brentuximab-vedotin induced injury","volume":"11","author":"Bankov","year":"2019","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.canlet.2020.12.015_bib38","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ijc.23119","article-title":"Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5\/Rantes in tumor cell growth and microenvironmental interactions","volume":"122","author":"Aldinucci","year":"2008","journal-title":"Int. J. Canc."},{"issue":"2","key":"10.1016\/j.canlet.2020.12.015_bib39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ijc.11370","article-title":"Expression of CCL5\/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue","volume":"107","author":"Fischer","year":"2003","journal-title":"Int. J. Canc."},{"issue":"12","key":"10.1016\/j.canlet.2020.12.015_bib40","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1038\/sj.leu.2403992","article-title":"Angiogenesis and mast cells in Hodgkin lymphoma","volume":"19","author":"Glimelius","year":"2005","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.canlet.2020.12.015_bib41","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0002-9440(10)65424-7","article-title":"High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma","volume":"154","author":"van den Berg","year":"1999","journal-title":"Am. J. Pathol."},{"issue":"25","key":"10.1016\/j.canlet.2020.12.015_bib42","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2020.12.015_bib43","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.canlet.2020.12.015_bib44","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2020.12.015_bib45","first-page":"2059","article-title":"The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2020.12.015_bib46","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/1471-2407-14-335","article-title":"Indoleamine 2,3-dioxygenase (Ido) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study","volume":"14","author":"Choe","year":"2014","journal-title":"BMC Canc."},{"issue":"1","key":"10.1016\/j.canlet.2020.12.015_bib47","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/cas.13432","article-title":"Clinical significance of tryptophan catabolism in Hodgkin lymphoma","volume":"109","author":"Masaki","year":"2018","journal-title":"Canc. Sci."},{"issue":"8","key":"10.1016\/j.canlet.2020.12.015_bib48","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4(+) regulatory T-cell-rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2020.12.015_bib49","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/1878-0261.12616","article-title":"High CD206 levels in Hodgkin lymphoma-educated macrophages are linked to matrix-remodeling and lymphoma dissemination","volume":"14","author":"Arlt","year":"2020","journal-title":"Mol Oncol"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520306650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520306650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:54:34Z","timestamp":1759593274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383520306650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":49,"alternative-id":["S0304383520306650"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2020.12.015","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2020.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}